DexCom, Inc. (DXCM) has a MoatMap StockRank of 87/100 based on Quality (77/100), Value (30/100), and Momentum (63/100) factor scores. The current signal is STRONG BUY. DexCom is a high-quality pioneer in continuous glucose monitoring (CGM). However, the stock faces near-term valuation headwinds and shifting market dynamics due to GLP-1 adoption, and it lacks direct alignment with our active 18-month macro themes.
DexCom, Inc. develops, manufactures, and markets innovative continuous glucose monitoring (CGM) systems for people with diabetes. The company is a market leader in real-time CGM technology, offering advanced, highly accurate, and user-friendly devices that significantly improve diabetes management. DexCom is expanding market access and enhancing its technology to serve a growing global diabetic population.
| Price | $72.59 |
| Market Cap | $27.9B |
| P/E (TTM) | 31.15 |
| P/E (Forward) | 23.66 |
| Price/Book | 9.47 |
| Return on Equity | 35.6% |
| Return on Invested Capital | 26.4% |
| Debt/Equity | 46.83 |
| Gross Margin | 61.5% |
| Operating Margin | 21.4% |
| Revenue Growth | 15.0% |
| Free Cash Flow | $1.1B |
DexCom, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).